GB201618424D0 - Treatment of antibody mediated disease - Google Patents
Treatment of antibody mediated diseaseInfo
- Publication number
- GB201618424D0 GB201618424D0 GBGB1618424.4A GB201618424A GB201618424D0 GB 201618424 D0 GB201618424 D0 GB 201618424D0 GB 201618424 A GB201618424 A GB 201618424A GB 201618424 D0 GB201618424 D0 GB 201618424D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- mediated disease
- antibody mediated
- antibody
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000037908 antibody-mediated disorder Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1618424.4A GB201618424D0 (en) | 2016-11-01 | 2016-11-01 | Treatment of antibody mediated disease |
| PCT/EP2017/077966 WO2018083122A1 (en) | 2016-11-01 | 2017-11-01 | Human fcrn binding antibody for use in treatment of antibody mediated disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1618424.4A GB201618424D0 (en) | 2016-11-01 | 2016-11-01 | Treatment of antibody mediated disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201618424D0 true GB201618424D0 (en) | 2016-12-14 |
Family
ID=57963530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1618424.4A Ceased GB201618424D0 (en) | 2016-11-01 | 2016-11-01 | Treatment of antibody mediated disease |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201618424D0 (en) |
| WO (1) | WO2018083122A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220152546A (en) | 2013-12-24 | 2022-11-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Fcrn antagonists and methods of use |
| MX2020005981A (en) * | 2017-12-08 | 2020-08-24 | Argenx Bvba | USE OF CRFN ANTAGONISTS FOR THE TREATMENT OF GENERALIZED MYASTENIA GRAVIS. |
| CN112513073A (en) * | 2018-06-08 | 2021-03-16 | 阿根思公司 | Compositions and methods for treating immune thrombocytopenia |
| JP7565951B2 (en) | 2019-06-07 | 2024-10-11 | アルジェニクス ビーブイ | Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration |
| US20210024620A1 (en) * | 2019-07-25 | 2021-01-28 | Genzyme Corporation | Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists |
| US12403175B2 (en) | 2020-01-08 | 2025-09-02 | argenx BV | Methods for treating pemphigus disorders |
| JP2025512483A (en) | 2022-04-13 | 2025-04-17 | オーエスイー・イミュノセラピューティクス | A novel class of molecules for selectively eliminating antibodies |
| WO2023242372A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | Fcrn/hsa binding molecules and methods of use |
| TW202432178A (en) * | 2023-01-06 | 2024-08-16 | 比利時商阿根思公司 | Methods for treating pots using fcrn antagonists |
| WO2025096432A1 (en) * | 2023-10-30 | 2025-05-08 | Q32 Bio Inc. | Treatment of anca-associated vasculitis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2606378A1 (en) * | 2005-04-29 | 2006-11-09 | The Jackson Laboratory | Fcrn antibodies and uses thereof |
| US8273351B2 (en) * | 2008-04-25 | 2012-09-25 | Dyax Corp. | Fc receptor binding proteins |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| KR20220152546A (en) * | 2013-12-24 | 2022-11-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Fcrn antagonists and methods of use |
| HUE056775T2 (en) * | 2015-03-09 | 2022-03-28 | Argenx Bvba | Methods of reducing serum levels of fc-containing agents using fcrn antagonsits |
-
2016
- 2016-11-01 GB GBGB1618424.4A patent/GB201618424D0/en not_active Ceased
-
2017
- 2017-11-01 WO PCT/EP2017/077966 patent/WO2018083122A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018083122A1 (en) | 2018-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264674B1 (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| IL256175A (en) | Use of exosomes for the treatment of disease | |
| IL253945A0 (en) | Kdm1a inhibitors for the treatment of disease | |
| PT3212233T (en) | Combination therapy for treatment of disease | |
| PL3283527T3 (en) | COMBINED TREATMENT OF CANCER | |
| GB201618424D0 (en) | Treatment of antibody mediated disease | |
| HUE059694T2 (en) | Preparation for the treatment of cancer | |
| SG11201701723XA (en) | Methods of treating liver disease | |
| MA41449A (en) | POLYTHERAPIES FOR THE TREATMENT OF CANCERS | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| HUE060517T2 (en) | Procedures for the treatment of immunodeficiency disease | |
| IL256103B (en) | Compounds and methods for the treatment of celiac disease | |
| LT3119384T (en) | TREATMENT OF INTRAHEPATIC CHOLESTAIN DISEASES | |
| GB201716733D0 (en) | Treatment of SMC mediated disease | |
| IL257764B (en) | Methods of treating diseases | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| IL256000A (en) | The quantification of the her 2 protein for optimal cancer treatment | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| GB201504387D0 (en) | Materials and methods for the treatment of vascular disease | |
| EP3145931A4 (en) | Treatment of autoimmune disease | |
| PL3484475T3 (en) | 1-methylnicotinamide for the treatment of cardiovascular disease | |
| IL253847A0 (en) | Methods of treating diseases | |
| KR20180084983A (en) | Uses of Pyrimido-Pyrimidazinone for the Treatment of Cancer | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| HUE063820T2 (en) | Methods for the treatment of cardiovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |